July 27, 2015
CASI Pharmaceuticals Appoints Leading Oncology Experts To Newly Formed Clinical Advisory BoardJuly 20, 2015
CASI Pharmaceuticals Announces Availability Of Anti-Cancer Drug Zevalin® In Hong Kong For Non-Hodgkin’s LymphomaJune 11, 2015
CASI Pharmaceuticals To Present At The 2015 BIO International ConventionJune 04, 2015
CASI Files New Drug Clinical Trial Application With China FDA To Expand U.S. Development Of ENMD-2076 In Fibrolamellar CarcinomaMay 15, 2015
CASI Pharmaceuticals Reports First Quarter 2015 Financial ResultsMarch 30, 2015
CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell CarcinomaMarch 27, 2015
CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial ResultsMarch 25, 2015
CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In ChinaMarch 04, 2015
CASI Pharmaceuticals Appoints Rong Chen, Md, Ph.D. As Chief Medical OfficerMarch 03, 2015
CASI Pharmaceuticals To Present At The 27th Annual Roth ConferenceFebruary 09, 2015
CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For The Treatment Of Patients With Fibrolamellar Carcinoma (FLC)February 02, 2015
CASI Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor ConferenceJanuary 16, 2015
CASI Pharmaceuticals Highlights 2014 Accomplishments And 2015 MilestonesDecember 23, 2014
CASI Pharmaceuticals To Hold Business Update Conference Call And Webcast On January 6thDecember 17, 2014
CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar CarcinomaNovember 14, 2014
CASI Pharmaceuticals Reports Third Quarter 2014 Financial ResultsNovember 12, 2014
CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue SarcomaSeptember 23, 2014
CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of DirectorsSeptember 18, 2014
Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its DrugsAugust 14, 2014
CASI Pharmaceuticals Reports Second Quarter 2014 Financial Results
